Starpharma Holdings (SPL)

Download button icon Download

Starpharma Holdings (SPL): Signals

No data currently available.

data-ad-format="auto">

Explore Compare Share

TECHNICAL ANALYSIS SUMMARY

Starpharma Holdings (SPL.AX)


Indicator:

ULCER INDEX


Last Signal:

BULLISH


Trading: BUY @ $1.36
Signal Strength: MEDIUM
Recommendation:

Volatility indicators highlight potential moves of a stock which can either move sharply in the updwards or downwards direction. This indicator allows stocks to be compared on a level playing field to highlight high and low volatility. Normally, falling markets are more likely to be volatile than a rising markets due to the emotion that gets tied to trading. Use volatility indicators in conjunction with other indicators to reduce exposure to false moves.


Starpharma Holdings (ASX:SPL) UIX index implies that the downside risk of the current trading price is high. Currently, the UIX is 6.774.



A technical indicator that measures downside risk in terms of both depth and duration of price declines. The Ulcer Index (UI) increases in value as the price moves farther away from a recent high and falls as the price rises to new highs. The indicator is usually calculated over 14 days with the UI showing the percentage drawdown a trader can expect from the high over that period. The greater the value of the UI the longer it takes for a stock to get back to the former high.

Calculation: Ulcer Index:
1) Percentage Drawdown = [(Close - 14-period High Close)/14-period High Close] x 100;
2) Squared Average = (14-period Sum of Percentage Drawdown Squared)/14;
3) Ulcer Index = Square Root of Squared Average;


PROFILE: Starpharma Holdings (SPL.AX)


Stock Exchange: ASX
Company: Starpharma Holdings
Ticker Codes: | SPL.AX | ASX:SPL |

About Starpharma Holdings (ASX:SPL):

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications primarily in Australia and Canada. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections. It also develops dendrimer-enhanced, or DEP versions of existing drugs, including DEP docetaxel that is in Phase I clinical trial for breast, prostate, lung, and ovarian tumor. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Top 10:

Ulcer Index

Download button icon Download
Company Close Change (%) Volume Value Signal
DNA Donaco International 0.05 22.7 60,506,628 7.67 BEARISH
AJX Alexium International 0.11 5 90,709 25.7 BEARISH
CSR CSR 2.82 4.8 6,128,296 5.95 BEARISH
BDR Beadell Resources 0.05 4.5 814,267 9.3 BEARISH
BRN Brainchip Holdings 0.12 4.3 567,310 6 BEARISH
RXP Rxp Services 0.48 4.3 13,174 11.4 BEARISH
EWC Energy World Corporation 0.15 3.4 402,205 5.73 BEARISH
NST Northern Star Resources 8.56 3.3 4,078,339 9.97 BEARISH
ZEL Zeolite Australia 5.41 3.2 11,794 13.91 BEARISH
PPH Pan Pharmaceuticals 3.15 2.9 56,084 6.91 BEARISH
back to top